The nomination of the Alfathon finalists took place during the first appointment with the INNOVATION TALKS, the Clubhouse room dedicated to technological innovation and health.
The United Nations marks April 21st as the World Creativity and Innovation Day. For that reason, Alfasigma launches INNOVATION TALKS, a Clubhouse room focused on innovation technologies and health.
v-WIN Foundation and Alfasigma together to fight one of the leading causes of preventable death: venous thrombosis.
Italy as the hub of an international public awareness project on venous and lymphatic health of the legs to be presented in DUBAI during the EXPO.
An innovative geo-localization software has being launched to increase knowledge & awareness about the disease.
Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis).
Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies and ventricular arrhythmia are the main pathologies in which we offer solutions.
In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles.
Nutraceuticals & Medical foods
With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue.